Atherosclerotic Cardiovascular Disease

Cardiovascular
8
Pipeline Programs
9
Companies
8
Clinical Trials
1 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
1
3
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
3100%
+ 6 programs with unclassified modality

On Market (2)

Approved therapies currently available

Regeneron
PRALUENTApproved
alirocumab
Regeneron
PCSK9 Inhibitor [EPC]injection2015
Amgen
REPATHAApproved
evolocumab
Amgen
PCSK9 Inhibitor [EPC]injection2015

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Regeneron
RegeneronTARRYTOWN, NY
1 program
1
1
AlirocumabPhase 3Monoclonal Antibody
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
EvolocumabPhase 4Monoclonal Antibody1 trial
Active Trials
NCT03096288Completed259Est. Nov 2020
Sanofi
SanofiPARIS, France
1 program
1
AlirocumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT01663402Completed18,924Est. Jan 2018
NewAmsterdam Pharma
NewAmsterdam PharmaNARRDEN, Netherlands
1 program
1
ObicetrapibPhase 31 trial
Active Trials
NCT05202509Active Not RecruitingEst. Nov 2026
CSL Behring
CSL BehringIL - Bradley
1 program
1
CSL300Phase 2/31 trial
Active Trials
NCT05485961Recruiting2,310Est. Sep 2029
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
2 programs
1
NNC0385-0434 A 15 mgPhase 21 trial
No treatment givenN/A1 trial
Active Trials
NCT07160829Completed608Est. Oct 2025
NCT04992065Completed267Est. Jun 2022
Alliance Pharmaceuticals
1 program
aspirinN/A2 trials
Active Trials
NCT02697916Completed15,076Est. Jun 2020
NCT00002527Completed635Est. Jan 2006
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
aspirinN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
AmgenEvolocumab
NewAmsterdam PharmaObicetrapib
SanofiAlirocumab
Alliance Pharmaceuticalsaspirin
CSL BehringCSL300
Novo NordiskNNC0385-0434 A 15 mg
Novo NordiskNo treatment given
Alliance Pharmaceuticalsaspirin

Clinical Trials (8)

Total enrollment: 38,079 patients across 8 trials

NCT03096288AmgenEvolocumab

Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity

Start: Oct 2017Est. completion: Nov 2020259 patients
Phase 4Completed
NCT05202509NewAmsterdam PharmaObicetrapib

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Start: Feb 2022Est. completion: Nov 2026
Phase 3Active Not Recruiting
NCT01663402SanofiAlirocumab

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Start: Oct 2012Est. completion: Jan 201818,924 patients
Phase 3Completed
NCT00002527Alliance Pharmaceuticalsaspirin

Aspirin in Treating Patients With Colorectal Cancer That Has Been Surgically Removed

Start: May 1993Est. completion: Jan 2006635 patients
Phase 3Completed
NCT05485961CSL BehringCSL300

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

Start: Oct 2022Est. completion: Sep 20292,310 patients
Phase 2/3Recruiting
NCT04992065Novo NordiskNNC0385-0434 A 15 mg

A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

Start: Aug 2021Est. completion: Jun 2022267 patients
Phase 2Completed
NCT07160829Novo NordiskNo treatment given

Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Heart Failure Management

Start: Sep 2025Est. completion: Oct 2025608 patients
N/ACompleted
NCT02697916Alliance Pharmaceuticalsaspirin

Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term

Start: Apr 2016Est. completion: Jun 202015,076 patients
N/ACompleted

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Territory Sales Manager - Iowa / Nebraska

HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
23h ago
From $150K/yr

Associate Regional Clinical Consultant

Johnson & Johnson
Amersfoort, Utrecht, Netherlands
Yesterday

Medical Affairs Sr Scientist- Electrophysiology

Johnson & Johnson
Irvine, California, United States of America
Yesterday
$92K - $148K/yr

Labeling Operations Specialist

Johnson & Johnson
Danvers, Massachusetts, United States of America
Yesterday

Physician Program Director, Great North

Johnson & Johnson
Danvers, Massachusetts, United States of America
Yesterday
$132K - $212K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 38,079 patients
9 companies competing in this space

Related Indications

Heart Failure(334)Hypertension(333)Coronary Artery Disease(295)Atrial Fibrillation(288)Pulmonary Arterial Hypertension(103)Acute Coronary Syndrome(62)Pulmonary Hypertension(55)Essential Hypertension(32)Coronary Heart Disease(28)Aortic Valve Stenosis(27)